Drugmaker AstraZeneca flags possible $4.5 million Chinese tax fine
AstraZeneca could face a fine of up to $4.5 million in China over suspected unpaid taxes related to the import of two of its cancer drugs, the pharmaceuticals giant said on Thursday as it continues to gauge the impact of ongoing investigations in the key growth market.